Boston-based biotechnology company Elektrofi revealed on Wednesday that it has appointed Paul Herbert to the role of senior vice president of Pharmaceutical Development.
The company said Herbert is a highly experienced senior executive with a proven track record of about 30 years in the pharmaceutical industry.
Herbert is a an expert in product development and manufacturing for particle-based products and has led the development of twelve processes to NDA submission.
Before joining Elektrofi, Herbert served as vice president of Process Development & Engineering at Alkermes, where he led teams of up to 100 individuals in all aspects of drug product operations, including sterile process design, regulatory documentation, CDMO/CMO management, and clinical manufacturing.
Elektrofi is focused on improving administration for a range of medicines, such as monoclonal antibodies, therapeutic proteins and other large molecule drugs. The company's breakthrough formulation platform is designed to enable stabilized, highly concentrated formulations for subcutaneous administration.
Galapagos plans to wind down cell therapy business following strategic review
Sebela's MIUDELLA Hormone-Free Copper IUS recognised in TIME's best inventions of 2025
Revelation Pharma acquires Acacia Apothecary & Wellness
Viatris receives fifth consecutive recognition on Forbes' annual list of World's Best Employers
INOVIO announces inducement grant to new employee
AbbVie's Allergan Aesthetics announces Natrelle supplier agreement with Vizient
Karyopharm Therapeutics awards inducement grants to new employees
POLYTECH Health & Aesthetics announces Poland expansion
Santhera Pharmaceuticals signs Gulf region distribution agreement with Uniphar